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CObjective: We report a cost-effectiveness evaluation of granulocyte
colony–stimulating factors (G-CSFs) for the prevention of febrile neu-
tropenia (FN) after chemotherapy in the United Kingdom (UK).
Methods: A mathematical model was constructed simulating the ex-
perience of women with breast cancer undergoing chemotherapy.
Three strategies were modeled: primary prophylaxis (G-CSFs adminis-
tered in all cycles), secondary prophylaxis (G-CSFs administered in all
cycles after an FN event), and no G-CSF prophylaxis. Three G-CSFs were
considered: filgrastim, lenograstim, and pegfilgrastim. Costs were
taken from UK databases and utility values from published sources. A
systematic review provided data on G-CSF efficacy. Probabilistic sensi-
tivity analyses examined the effects of uncertainty in model
parameters. Results: In the UK, base-case analysis with a willingness-
o-pay (WTP) threshold of £20K per quality-adjusted life year gained
nd also using list prices, the most cost-effective strategy was primary
rophylaxis with pegfilgrastim for a patient with baseline FN risk O
of Sh
al So
doi:10.1016/j.jval.2010.10.037reater than 38%, secondary prophylaxis with pegfilgrastim for base-
ine FN risk 11% to 37%, and no G-CSFs for baseline FN risk less than
1%. Using a WTP threshold of £30K and list prices, primary prophy-
axis with pegfilgrastim was cost-effective for baseline FN risks greater
han 29%. In all analyses, pegfilgrastim dominated filgrastim and le-
ograstim. Sensitivity analyses demonstrated that higher WTP thresh-
ld, younger age, earlier stage at diagnosis, or reduced G-CSF prices
esult in G-CSF prophylaxis being cost-effective at lower baseline FN
isk levels. Conclusion: Pegfilgrastim was the most cost-effective G-
SF. The most cost-effective strategy (primary or secondary prophy-
axis) was dependent on the FN risk level for an individual patient,
atient age and stage at diagnosis, and G-CSF price.
eywords: cost-effectiveness, economic model, febrile neutropenia,
ranulocyte colony–stimulating factors, prophylaxis.
opyright © 2011, International Society for Pharmacoeconomics and
utcomes Research (ISPOR). Published by Elsevier Inc.Introduction
Neutropenia is the major dose-limiting toxicity of many chemo-
therapy regimens. Febrile neutropenia (FN) and its conse-
quences are associated with substantial morbidity, mortality,
and costs [1]. Chemotherapy-induced neutropenia and FN are
also associated with dose reductions and delays to chemother-
apy that can compromise patient survival [2].
In the United Kingdom (UK), the National Confidential En-
quiry into Patient Outcome and Death (NCEPOD) performed a
review of the care of patients who died within 30 days of receiv-
ing systemic anticancer therapy (SACT) [3]. They found that the
most commonly reported grade 3-4 toxicities associated with
patients dying within 30 days of chemotherapy were neutrope-
nia, neutropenic sepsis, and infection.
Recombinant human granulocyte colony–stimulating factors
(G-CSFs) stimulate production of mature, functional neutrophils
[4] that reduce the duration and severity of neutropenia and the
incidence of FN when used as prophylaxis alongside chemother-
apy [5,6]. G-CSF prophylaxis may be beneficial during treatment
* Address correspondence to: Sophie Whyte, ScHARR, University
Kingdom.
E-mail: sophie.whyte@sheffield.ac.uk.
1098-3015/$36.00 – see front matter Copyright © 2011, Internation
Published by Elsevier Inc.for many different cancers, depending on the risk of FN, which is a
factor of combined chemotherapy regimen and patient risk factors
[7]. This analysis focuses on breast cancer because the evidence
base for G-CSF prophylaxis is well developed in this setting. Three
G-CSFs were in use at the time of this analysis: filgrastim, pegfil-
grastim, and lenograstim. Pegfilgrastim is given as a single injec-
tion per chemotherapy cycle. Filgrastim and lenograstim prophy-
laxis both involve administration of a number of daily injections
per cycle. It is recommended that filgrastim and lenograstim be
given daily until the neutrophil count returns to the normal range
(for up to 14 days per cycle for filgrastim or up to 28 days for
lenograstim) [8,9].
G-CSFs can be administered as primary prophylaxis (in all cy-
cles) or as secondary prophylaxis (in all remaining cycles after an
episode of FN). A 2003 UK audit of 422 breast cancer patients found
that only 3.6% of patients received prophylactic G-CSFs and all use
was as secondary prophylaxis [10]. The introduction of newer
breast cancer chemotherapy regimens such as TAC (docetaxel,
doxorubicin, and cyclophosphamide) and FEC-T (fluorouracil, epi-
rubicin, and cyclophosphamide, docetaxel) associated with higher
effield, Regent Court, 30 Regent Street, Sheffield, S1 4DA United
ciety for Pharmacoeconomics and Outcomes Research (ISPOR).
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466 V A L U E I N H E A L T H 1 4 ( 2 0 1 1 ) 4 6 5 – 4 7 4FN risks may further increase the need for primary prophylaxis
[11].
Clinical guidelines on the use of G-CSFs have been produced by
the European Organisation for Research and Treatment of Cancer
(EORTC) [7] and also in the United States (US) by the American
Society of Clinical Oncology (ASCO) [12] and the National Compre-
hensive Cancer Network (NCCN) [13]. All sets of guidelines recom-
mend that prophylactic G-CSFs should be used where the risk of
FN associated with the chemotherapy regimen is greater than or
equal to 20% and may be considered where the risk is 10% to 20%,
particularly where additional patient risk factors are present.
The objective of this study was to model the cost-effectiveness
of G-CSF prophylaxis of FN in patients with breast cancer com-
pared to no G-CSF provision. In the analyses, seven prophylaxis
strategies were evaluated: primary prophylaxis and secondary
prophylaxis for each of three G-CSFs (pegfilgrastim, filgrastim, and
lenograstim) and no G-CSF prophylaxis.
Methods
Model structure
A mathematical model was constructed using TreeAge Software
(TreeAge Software Inc., Williamstown, MA) to estimate the costs
and quality-adjusted life years (QALYs) accrued by different strat-
egies of G-CSF use. The model provided the basis for a submission
to the All Wales Medicines Strategy Group, and this body subse-
quently recommended pegfilgrastim for use both as primary and
Fig. 1 – Factors affectsecondary prophylaxis in the National Health Service (NHS) in sWales [14]. A lifetime horizon was used because an FN episode
may affect patient survival.
The modeling approach conforms to the National Institute for
Health and Clinical Excellence (NICE) methods guidance [15]. The
odel takes the perspective of the UK NHS and was populated
ith UK data where possible. A meta-analysis was performed to
btain efficacy data, EQ-5D utility values were used, and future
osts and benefits were discounted at a rate of 3.5% per annum.
The base case for the analysis consisted of a cohort of 52-year-
ld female patients diagnosed with stage 2 breast cancer in line
ith data on presenting characteristics [16,17]. In line with the
ICE reference case, willingness-to-pay (WTP) thresholds of
20,000 and £30,000 were used [15] to calculate net monetary ben-
fit (NMB).
The majority of clinical trials of filgrastim and lenograstim
longside chemotherapy cycles of 3-week duration used approxi-
ately 11 injections per cycle, at which point the neutrophil count
ad generally recovered [5,18,19]. Therefore, we assumed that 11
ays of treatment with either lenograstim or filgrastim is consis-
ent with the efficacy evidence of randomized, controlled trials.
Several FN risk factors and breast cancer survival risk factors
re included in the modeling, and these relationships are shown in
igure 1 and discussed in the following.
The model structure is shown in Figure 2. A regimen consisting
f six chemotherapy cycles of 21 days each is modeled, and in each
hemotherapy cycle, a patient may or may not experience an FN
vent. A regimen of six cycles was modeled because this is the
umber of cycles commonly given for breast cancer in the UK. An
N event may cause chemotherapy dose delays/reductions (i.e.,
N risk and survival.ing Fuboptimal relative dose intensity [RDI]), which may affect patient
467V A L U E I N H E A L T H 1 4 ( 2 0 1 1 ) 4 6 5 – 4 7 4survival. After chemotherapy, the model uses a state transition
model with a cycle length of 1 year. Life expectancy is estimated
using breast cancer survival data (which are dependent on stage at
diagnosis). Patients may die of FN during chemotherapy and of
breast cancer or other causes after chemotherapy. During chemo-
therapy, only deaths caused by FN were considered, but postche-
motherapy deaths from breast cancer and other causes were con-
sidered.
One- and two-way sensitivity analyses were undertaken.
Probabilistic sensitivity analyses were run using 10,000 sets of
parameters sampled independently from the distributions de-
scribed in Table 1. Distributions used were taken from pub-
lished sources where available; otherwise they were chosen to
fit to published 95% confidence intervals (CIs). Further details on
choice of distributions are given in the data population section.
The appropriateness of 1000 configurations was tested using
jackknife techniques [20], which on an example data set showed
that the CI around a mean cost per QALY was small (£500 in all
cases).
Data population
Calculating FN risk for patients receiving no prophylaxis
Baseline risk, defined as the likelihood of having at least one FN
episode over all cycles of chemotherapy without G-CSF provi-
sion, can vary widely among patients. The EORTC guidelines
show that baseline risk can vary from 1% to 71%, depending on
chemotherapy regimen, patient age, performance status, and
other risk factors [7]. It has also been established that the risk of
an initial FN episode is greatest in chemotherapy cycle 1
[6,21,22]. The relative risk of an initial FN event in cycles 2 on-
ward compared with cycle 1 was calculated as 0.2 (95% CI:
0.154 – 0.293) using data from a study that distinguished be-
tween initial and subsequent FN events [21]. In addition, occur-
rence of an FN event indicates that a patient is at a higher risk of
further FN events in subsequent cycles. The relative risk of fur-
ther FN episodes in a patient with previous episodes was calcu-
lated as 9.09 (95% CI: 6.19 –13.35), using data from a study that
reported first occurrence of FN events by cycle [21]. Log-normal
distributions fitted to these CIs were used for these FN-related
Fig. 2 – Schematic of threlative risks.To inform decision making for a broad population of patients,
we modeled the cost-effectiveness of G-CSF for a range of baseline
risk values. Our model required the FN risk per cycle, which we
calculated from the baseline risk using the information given ear-
lier and assuming six cycles of chemotherapy. For example, to
model a baseline FN risk of 20%, this was split into a cycle 1 risk of
10% and a risk of 2% for each of cycles 2 through 6. If a patient had
an FN episode in cycle 1, this increased the FN risk in each subse-
quent cycle to 18%. Further details on these calculations are given in
Appendix 1 available at: doi:10.1016/j.jval.2010.10.037.
G-CSF efficacy
A full systematic review of literature relating to G-CSF efficacy was
undertaken. The comparative efficacy of the three G-CSFs in re-
ducing FN risk was evaluated using meta-analyses of trials of each
G-CSF compared to no primary G-CSF prophylaxis (Table 2). This
work updated an existing meta-analysis by Kuderer et al. [23] and
will be published separately. Details of the trials of the pegfilgras-
tim versus no G-CSF are included in Appendix 2 available at: doi:
10.1016/j.jval.2010.10.037. In line with NICE methods guidance, the
results of the meta-analysis were used in the base-case analysis.
Log-normal distributions fitted to the CIs from the meta-analysis
were used to represent uncertainty in G-CSF efficacy relative risk
values.
In general, the studies included in the meta-analysis by Kud-
erer et al. [23] described administration of filgrastim/lenograstim
for approximately 11 days when the chemotherapy cycle length
was 3 weeks. The use of filgrastim and lenograstim for 6 days was
also considered because a 2003 UK audit of breast cancer patients
found that such a regimen is sometimes used, although the num-
ber of patients in this audit was small (n 15) [10]. A United States
(US) observational study of 205 breast cancer patients also found
that patients received on average 6 days of filgrastim per cycle [24].
Clinically, it is expected that 6-day filgrastim is less efficacious
than 11-day filgrastim because trial evidence indicates that neu-
trophil count does not fully recover until around 11 days of filgras-
tim treatment [5,18,19]. Trial evidence relating to using filgrastim
or lenograstim for 6 days is limited and inconclusive [21,25]. We
therefore conservatively assumed the efficacy for 6-day use to be
the same as that for 11-day use; this assumption is favorable to the
cision analytic model.e de6-day strategy.
468 V A L U E I N H E A L T H 1 4 ( 2 0 1 1 ) 4 6 5 – 4 7 4Mortality rates used within the model
A study by Kuderer et al. [1] analyzed 3077 breast cancer patients
hospitalized for FN in the US between 1995 and 2000. The mortality
rate for FN for breast cancer patients was 3.6% (95% CI: 2.9%–4.3%),
and a normal distribution was used to model uncertainty.
Breast cancer survival data are dependent on the stage at diag-
nosis and years since diagnosis. Data from Cancer Research UK
2007 for patients diagnosed in 1985 give survival rates by cancer
stage at diagnosis and years since diagnosis; with survival rates at
10 years of 78%, 55%, 28%, and 5% for stages 1 through 4, respec-
Table 1 – Summary of parameters used in model: determin
analyses, and references.
Variable Value
Costs
Pegfilgrastim per injection £686.38
Filgrastim per injection £98.39
Lenograstim per injection £111.83
Administrating a G-CSF injection £21.00
TAC chemotherapy per cycle £1,234.00
Hospitalization per day £235.00
Intravenous antibiotics during hospitalization £47.23
Daily investigations (per day of hospitalization) (full
blood count, urea, and electrolytes)
£9.27
Once-per-FN investigation (per FN) (1 mid stream urine
test, 2 blood cultures, 2 swabs, 1 x-ray)
£47.86
Average duration of hospitalization for an FN event (in
days): breast cancer
8
Rate used for discounting costs and QALYs 0.03
RDI and mortality inputs
Probability of dying from an FN event 0.03
Risk of RDI 85% if 65 years and no FN 0.24
Odds ratio for RDI 85% if patient 65 years 1.51
Odds ratio of having RDI 85% if patient has had FN event 1.58
Hazard ratio if low RDI (85%) 1.73
FN risk
Relative risk of an FN event with pegfilgrastim primary
prophylaxis vs. no G-CSF
0.30
Relative risk of Neupogen (filgrastim) for 11 days vs. no
G-CSF
0.57
Relative risk of lenograstim vs. no G-CSF 0.62
Relative risk of an FN event if patient has already had an
FN event
9.08
Relative risk of an FN event in cycles 2–6 vs. cycle 1 0.21
Utility multipliers (these are multiplied by an age-specific
average utility value from Kind et al., 1998 [32])
Breast cancer: undergoing chemotherapy treatment 0.7
Breast cancer: undergoing chemotherapy treatment–
multiplier
0.84
FN event hospitalization 0.33
FN event hospitalization–multiplier 0.39
First year after chemotherapy and subsequent years 2–5 0.85
Cancer survivors after year 5 0.87
Years 20 onward (from diagnosis), utility multiplier for
disease-free survival
0.94
Utility multiplier for local regional breast cancer 0.74
Utility multiplier for metastatic breast cancer 0.5
CI, confidence interval; FN, febrile neutropenia; G-CSF, granulocyte c
dose intensity.tively [26]. More recent survival data from 2001 to 2003 show breastcancer survival at 1, 5, 10, 15, and 20 years as 94%, 80%, 72%, 68%, and
65%, respectively, for all stages combined [27]. The relative propor-
tion of patients in each stage at diagnosis is 39%, 48%, 8%, and 5% for
stages 1 through 4, respectively [28], and it was assumed that im-
provements in survival since 1985 affect all stages equally. After ad-
justment, breast cancer survival rates at 10 years were calculated as
86%, 70%, 46%, and 16% for stages 1 through 4, respectively.
A limitation of these data is that they relate to all breast cancer
patients, not just those who undergo chemotherapy. It is not clear
in which direction this will bias results because the fact that a
values, distribution used in probabilistic sensitivity
Distribution Source
ssumed fixed British National Formulary [43]
ssumed fixed British National Formulary [43]
weight-based dose 5 g/kg/day
ssumed fixed British National Formulary [43]
weight-based dose 5 g/kg/day
ssumed fixed Curtis 2007 [49]
ssumed fixed Ward et al. 2007 [39]
ssumed fixed Curtis 2007 [49]
ssumed fixed British National Formulary [43]
ssumed fixed Sweetenham et al. 1999 [50],
uplifted to 2007
ssumed fixed Sweetenham et al. 1999 [50],
uplifted to 2007
ormal (mean 8, SD 0.2041) Kuderer et al. 2006 [1]
National Institute for Health and
Clinical Excellence, 2008 [15]
ormal (mean 0.036, SD 0.00357) Kuderer et al. 2006 [1]
ormal (mean 0.247, SD 0.05) Shayne et al. 2006 [2]
og-normal (mean of logs
0.4072, SD of logs 0.0993)
Shayne et al. 2006 [2]
og-normal (mean of logs
0.4472, SD of logs 0.1428)
Shayne et al. 2006 [2]
og-normal (mean of logs
0.5284, SD of logs 0.1987)
Chirivella et al. 2009 [31]
og-normal (mean of logs
1.2807, SD of logs 0.3917)
See Table 1
og-normal (mean of logs
0.5664, SD logs 0.0926)
See Table 1
og-normal (mean of logs
0.4886, SD of logs 0.1754)
See Table 1
og-normal (mean of logs
2.1878, SD of logs 0.1961)
Calculated from data in von
Minckwitz et al. 2008 [21]
og-normal (mean of logs
1.5621, SD of logs 0.1635)
Calculated from data in von
Minckwitz et al. 2008 [21]
ange 0.5–1 Hillner et al. 1992 [33]
eta (9.9, 1.8) 95% CI: 0.6–0.98
ange 0.24–0.42 Brown et al. 2001 [35]; Brown and
Hutton 1998 [34]
eta (30.7, 46.5) 95% CI: 0.29–0.51
Hind et al. 2007 [36]
Hind et al. 2007 [36]
eta (3.44, 0.21) Hind et al. 2007 [36]
eta (1.36, 0.48) Hind et al. 2007 [36]
eta (2.75, 2.75) Hind et al. 2007 [36]
–stimulating factor; QALYs, quality-adjusted life years; RDI, relativeistic
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469V A L U E I N H E A L T H 1 4 ( 2 0 1 1 ) 4 6 5 – 4 7 4mance status, but it may also indicate advanced disease and
hence an increased risk of mortality.
Mortality data from other causes are taken from Office for Na-
tional Statistics data [16].
Reduced relative dose intensity (RDI) of chemotherapy
Reduced RDI is commonly defined as receipt of less than 85% of the
planned chemotherapy dose intensity (either as a result of a reduced
dose or a delay between doses) [2,29]. Being aged 65 years or older and
having a history of an FN event are both predictors of receiving a
reduced RDI [2,30]. Because age is also a predictor of FN [30], age and
FN are not independent as predictors of RDI. The correlation between
these variables was explicitly modeled by Shayne et al. [2] using a
ultivariate logistic regression analysis. The reported odds ratios
ere used to calculate the risk of having a reduced RDI for the fol-
owing four groups: age younger than 65 years without a previous FN
vent, age younger than 65 years with a previous FN event, age 65
ears and older without a previous FN event, and age 65 years and
lder with a previous FN event (Table 3). Log-normal distributions
ere used to model uncertainty in these odds ratios.
Impact of RDI on survival
The relationship between chemotherapy dose intensity and
survival is uncertain. However, it is generally considered that a
reduction in RDI below the optimum is likely to be detrimental
to long-term survival of cancer [29]. In particular, in situations
n which dose-dense or dose-intense chemotherapy strategies
re used, a reduction in RDI may be detrimental to survival [7].
Table 2 – Relative risk of FN incidence with G-CSF prophyla
G-CSF prophylaxis Source
Pegfilgrastim Vogel et al., 2005 [6]; Balducci et al.
Romieu et al., 2007 [37]; Hecht et
Filgrastim (11 days) Kuderer et al., 2007 [23]; del Giglio e
Filgrastim (6 days) Assumed same as 11 days
Lenograstim (11 days) Kuderer et al., 2007 [23]
Lenograstim (6 days) Assumed same as 11 days
CI, confidence interval; FN, febrile neutropenia; G-CSF, granulocyte c
Table 3 – Relationship between age, previous FN, and
relative dose intensity.
Proportion of patients with RDI 85%*
All patients (N  3707) 29.7%
Age 65 years (n  2998) 26.9%
Age 65 years (n  709) 41.4%
FN (no. not reported) 36.0%
Odds ratios for risk of reduced RDI*
Age 65 years vs. age 65 years 1.51 (95% CI: 1.24–1.83)
Previous FN event vs. no previous
FN event
1.58 (95% CI: 1.20–2.10)
Probability of having a low RDI based
on age and previous FN events
Aged 65 years, no previous FN (BR) 24.7% (95% CI: 14.9%–34.5%)
Aged 65 years, previous FN 34.1%†
Aged 65 years, no previous FN 33.1%†
Aged 65 years, previous FN 43.9%†
CI, confidence interval; FN, febrile neutropenia; RDI, relative dose
intensity.
* Data from Shayne et al. [2].
† Calculated using odds ratio and formula: BR/[OR (1  BR)  BR],a
where BR  baseline risk and OR  odds ratio.Estimations can be made either from prospective trials that
ry to determine the optimal dose or from retrospective studies,
ut both have limitations. In prospective studies, there is likely
o be a ceiling above which further dose increases will not in-
rease survival. Long-term retrospective studies may be con-
ounded by the fact that patients who have their dose intensity
educed may be those who are more likely to die due to other
actors such as older age and poorer performance status. A ret-
ospectivestudybyChirivellaetal. [31] reportsahazardratio (HR)of1.73
or survival associated with an RDI of 85% or more versus an RDI less
han 85%. In this study, 88% of patients received an RDI of 85% or
ore and 12% received an RDI less than 85%.
The reciprocal of the reported HR was used to estimate mortal-
ty rates for low and high RDIs from the mean age–dependent
ortality rate as follows:
ean mortality  (probability RDI85% )
 mortality if RDI 85% )  (probability of RDI 85% )
 (mortality if RDI 85% ).
Hence, rearranging, we get the following: mortality if the RDI
85% mean mortality/(12%  88% * HR) and mortality if the RDI
85%  mean mortality * HR/(12%  88% * HR).
The model applies this HR to survival of patients with low RDI
for the remainder of their lifetime. As mentioned previously, the
retrospective nature of the Chirivella et al. study may result in
confounding. For this reason, a sensitivity analysis in which low
RDI has no effect on survival was included.
Utility values
Utility values that are dependent on both health state and patient
age were used. The average population utilities, categorized by
age, were taken from Kind et al. [32]. Each adverse health state (FN,
receiving chemotherapy for breast cancer, local or regional recur-
rence, distant metastases, and disease free) is assumed to be as-
sociated with a decreased utility for the duration of the event. Each
chemotherapy cycle is assumed to last for 3 weeks, and the mean
length of hospitalization after an FN event is estimated to be 8
days [1].
Utility values for the health states FN and receiving chemo-
therapy for breast cancer were reported as 0.33 and 0.70, respec-
tively [33–35]. These were converted into utility multipliers of
0.398 and 0.843, respectively (by dividing by 0.83 the age factor for
age 55 [32], assuming published utility is for patients aged 55).
Utility multipliers for disease-free state, local or regional recur-
rence, and distant metastases were taken from Hind et al. 2007 [36]
Table 1). For cancer survivors in years 1 through 5, it is assumed
hat 77% are disease free, 7% have local or regional recurrence, and
6% have distant metastases [36]. These proportions were com-
ined with the relevant multipliers to produce an average utility
ultiplier of 0.855. For cancer survivors in years 6 through 20, it is
stimated from Office for National Statistics survival data that 81%
Relative risk of FN compared to no G-CSF
prophylaxis, (95% CI), P value
[46];
009 [47]
0.30 (0.14–0.65), 0.002
2008 [48] 0.57 (0.48–0.69), 0.00001
0.57 (0.48–0.69), 0.00001
0.62 (0.44–0.88), 0.007
0.62 (0.44–0.88), 0.007
–stimulating factor.xis.
, 2007
al., 2
t al.,re disease free, 9.5% have local or regional recurrence, and 9.5%
ao
4
470 V A L U E I N H E A L T H 1 4 ( 2 0 1 1 ) 4 6 5 – 4 7 4have distant metastases; hence, an average utility multiplier of
0.879 was used. For 20 years post-diagnosis, it was assumed that
patients were disease free, and a utility multiplier of 0.94 was
used. Beta distributions were used to model uncertainty in utility
values.
Valuation of costs
All cost parameters were taken from UK sources. For other pa-
rameter values where UK data sources were not available, the
best quality non-UK data sources identified were used. Only
costs incurred during the time on chemotherapy were included
in the model. It was assumed that costs incurred after chemo-
therapy was completed were independent of G-CSF prophylaxis
strategy.
The unit costs used in the model are given in Table 1. It is
assumed that G-CSF injections are administered by a district nurse
in the patient’s home. It is assumed that FN treatment is admin-
istered on an inpatient basis. Filgrastim and lenograstim were as-
sumed to be administered as weight-based doses at 5 g/kg/day.
Patient weights were reported in three of the studies, and a
weighted mean was calculated to be 72.3 kg (SD 14.7 kg) [5,37,38].
Using this patient weight distribution, the following vial size re-
quirements were calculated: 20% of patients weigh less than 60 kg
and require a single 300-g vial, 74% of patients weigh 61 to 96 kg
nd require a single 480-g vial, and 5% of patients weigh at least
97 kg and require two 300-g vials. Similarly for lenograstim, 10%
f patients weigh less than 53 kg and require a single 263-g vial,
5% of patients weigh 54 to 74 kg and require a 263-g vial plus a
105-g vial, and 45% of patients weigh at least 75 kg and require
Table 4 – Probabilistic sensitivity analyses results.
Cost
(£)
QALYs
c
Base case: TAC chemotherapy, 24% FN risk
level, age 52 years, stage 2 at diagnosis
No G-CSFs† 8282 10.060
Secondary prophylaxis with lenograstim
for 11 days
9250 10.083
Secondary prophylaxis with lenograstim
for 6 days
8744 10.083
Secondary prophylaxis with filgrastim for
11 days
9134 10.084
Secondary prophylaxis with filgrastim for
6 days
8679 10.084
Secondary prophylaxis with pegfilgrastim 8556 10.103
Primary prophylaxis with lenograstim for
11 days
16,607 10.136
Primary prophylaxis with lenograstim for
6 days
12,637 10.136
Primary prophylaxis with filgrastim for 11
days
15,715 10.138
Primary prophylaxis with filgrastim for 6
days
12,147 10.138
Primary prophylaxis with pegfilgrastim 11,841 10.188
Second example analysis: ET chemotherapy,
31% FN risk level, age 52 years, stage 2
at diagnosis
No G-CSFs 8658 9.989
Secondary prophylaxis with pegfilgrastim 8910 10.059
Primary prophylaxis with pegfilgrastim 11,910 10.170
Dominated, another strategy has higher effectiveness and lower cost
ICER, incremental cost-effectiveness ratio; Incr., incremental; NMB, n
to pay.
* ICERs are only presented for strategies on the cost-effectiveness fr
on the cost-effectiveness frontier.
† For the ‘No G-CSFs’ stategies the incrementals are not calculated so dastwo 263-g vials. Because the G-CSF market in the UK is driven by
competitive tenders, it is common for discounts to be provided on
list prices. Therefore, various discounted prices were considered
in a sensitivity analysis.
The costs of chemotherapy are dependent on the number of
chemotherapy cycles received. If a patient dies of an FN event
during chemotherapy, no further cycles are given and no further
costs are incurred. Chemotherapy costs vary depending on the
regimen. For simplicity, the cost of TAC is used at £1234 per cycle
[39]. Costs of chemotherapy were assumed independent of the RDI
rate.
Results
Results are presented for a baseline FN risk of 24%, the mean risk
for a patient receiving TAC chemotherapy [7]. We calculate the
incremental costs and QALYs compared to a strategy of no G-CSF
prophylaxis. These are presented alongside the NMBs and incre-
mental cost-effectiveness ratio (ICER) in Table 4. At this risk level,
the ICER for primary prophylaxis with pegfilgrastim is £38,482. The
cost-effectiveness acceptability curve (CEAC) [40] is shown in Fig-
ure 3. All strategies are presented in the CEAC, but only primary
and secondary pegfilgrastim and no G-CSFs have a probability of
0.05 of being cost-effective, so the other strategies are very close
to the x-axis. With a WTP threshold of between £20,000 and
£30,000 per QALY, secondary prophylaxis with pegfilgrastim is the
most cost-effective strategy more than 90% of the time. We also
calculated results for the regimen epirubicin-docetaxel (ET75),
.
£)
Incr.
QALYs
Incr. NMB (£),
WTP  £20K
Incr. NMB (£),
WTP  £30K
ICER*
— — —
0.023 509 279 Dominated
0.023 3 227 Dominated
0.024 382 147 Dominated
0.024 73 308 Dominated
0.042 570 992 £6500
0.075 6816 6061 Dominated
0.075 2846 2091 Dominated
0.077 5891 5120 Dominated
0.077 2322 1551 Dominated
0.128 1008 268 £38,482
— — —
0.069 1131 1823 £3651
0.181 368 2178 £26,824
, febrile neutropenia; G-CSF, granulocyte colonystimulating factor;
netary benefit; QALYs, quality-adjusted life-years; WTP, willingness
. The ICER is calculated compared to the next less effective strategyIncr
ost (
—
968
462
852
397
274
8326
4355
7434
3865
3559
—
253
3252
s; FN
et mo
ontierhes are presented. For all the other strategies these are minus signs.
471V A L U E I N H E A L T H 1 4 ( 2 0 1 1 ) 4 6 5 – 4 7 4which is reported to have an FN risk of 31% (Table 4) [41,42]. At this
risk level, the ICER for primary prophylaxis with pegfilgrastim is
£26,824.
Results are highly sensitive to baseline FN risk. The base-case
analysis with a WTP threshold of £20,000 per QALY demonstrated
that for a patient with an FN risk level of 11% to 37%, secondary
prophylaxis with pegfilgrastim is most cost-effective, and for pa-
tients with higher FN risk levels, primary prophylaxis with pegfil-
Fig. 3 – Cost-effectiveness acceptability curves for base-case
52 years, stage 2 at diagnosis, list price G-CSFs).
GCSF co
GCSF co
Ag
Ag
Sta
Sta
0% 20% 40% 60% 80%
GCSF costs 50% discount
GCSF costs 30% discount
GCSF costs 10% discount
Age 65 at diagnosis
Age 40 at diagnosis
Stage 3 at diagnosis
Stage 1 at diagnosis
Base Case*
Patient baseline FN ris
WTP=£20K
No G-CSFs
Secondary prophylaxis with pegfilgrastim
Primary prophylaxis with pegfilgrastim
Sensitivity Analyses:Op
GCSF coFig. 4 – Sensitivity analyses: the G-CSF strategy with higrastim becomes the most cost-effective. Using a WTP threshold of
£30,000, primary prophylaxis with pegfilgrastim was cost-effective
for baseline FN risks greater than 29%.
Deterministic one-way sensitivity analysis on baseline FN risk
level was performed for a selection of scenarios, and results are pre-
sented in Figure 4. For a particular chemotherapy regimen, the base-
line FN risk, and therefore the cost-effectiveness of G-CSF prophy-
laxis, will vary for individual patients depending on patient risk
lysis (base-case: TAC chemotherapy, 24% FN risk level, age
0% 20% 40% 60% 80% 100%
0% discount
0% discount
t diagnosis
t diagnosis
t diagnosis
t diagnosis
Base Case*
Patient baseline FN risk
WTP = £30K
100%
 Strategy for each level of FN risk
0% discountanasts 5
sts 1
e 65 a
e 40 a
ge 3 a
ge 1 a
k
timal
sts 3ghest NMB for different levels of baseline FN risk.
472 V A L U E I N H E A L T H 1 4 ( 2 0 1 1 ) 4 6 5 – 4 7 4factors such as performance status and age. A clinician would be
assumed to estimate the risk of FN for an individual patient accord-
ing to factors such as performance status and the chemotherapy
regimen that he or she was receiving. As age increases, there will be
a decrease in remaining expected QALYs but an increase in the ex-
pected baseline FN risk, which affect the cost-effectiveness in oppos-
ing directions.
The scenario analyses performed demonstrate that age at di-
agnosis, stage at diagnosis, WTP threshold, and G-CSF price all
significantly affect the level of baseline FN risk at which G-CSF
prophylaxis becomes cost-effective. The scale of the effect that
these variables can have on the ICER is shown in a tornado dia-
gram in Figure 5.
We observe that all the strategies involving the once-daily G-
CSFs filgrastim and lenograstim are never optimal. Our analysis
indicated that pegfilgrastim would dominate filgrastim and le-
nograstim given for 11 days (because pegfilgrastim has lower cost
and higher efficacy) and had small ICERs compared to 6-day treat-
ment courses. As previously mentioned, trial evidence relating to
using filgrastim or lenograstim for 6 days is limited and inconclu-
sive. We note that if 6-day filgrastim was assumed to be less effec-
tive than 11-day filgrastim, this would result in lower expected
QALYs and slightly higher expected costs for 6-day filgrastim com-
pared to 11-day filgrastim. As discussed earlier, evidence compar-
ing the efficacy of 6- and 11-day filgrastim/lenograstim is incon-
clusive but, as an example, if the relative risk of FN for 6-day
filgrastim versus no G-CSF was 0.8, then primary prophylaxis with
6-day filgrastim is associated with an expected 10.102 QALYs and
£12,330.
Discussion
The most cost-effective strategy is dependent on the estimated
baseline risk of FN for an individual patient, the cost per QALY
threshold, patient age and stage at diagnosis, and G-CSF price. It is
noted that in all scenarios, the most cost-effective strategy was
one of primary pegfilgrastim, secondary pegfilgrastim, or no G-
CSFs. All strategies involving 11-day filgrastim or lenograstim
were dominated by a strategy involving pegfilgrastim. In no sce-
nario was the use of 6-day treatment with filgrastim or lenogras-
tim the most cost-effective strategy.
This study had several limitations. Several assumptions had to
Incremental Cost/Eff
0K 30K 60K 90K
P
D
A
H
C
Fig. 5 – Tornado diagram for primary prophylaxis with pegfi
pegfilgrastim.be made because of limitations in the data available. For example,UK-specific data were not available for all parameter values, so
data from other countries were used. A statistical analysis relating
patient age, performance status, and chemotherapy to FN risk was
not available, but the modeling would be improved if the relation-
ship between these factors was included. The availability of fur-
ther data reporting FN events with details of chemotherapy cycle
number and initial FN events would make the modeling more
robust.
If an FN event leads to reduced RDI, then this could lead to
higher breast cancer recurrence rates; hence, breast cancer treat-
ment costs may be higher for strategies that result in more FN
events. There are very limited data to estimate the change in treat-
ment costs because of a low RDI, and there is considerable uncer-
tainty surrounding the relationship between FN and RDI and RDI
and survival. Therefore, the modeling of costs was simplified by
assuming all postchemotherapy costs were the same, indepen-
dent of prophylaxis strategy. This assumption that the postche-
motherapy costs are the same for all strategies may bias against
G-CSF use.
Sensitivity analyses for stage at diagnosis and age at diagnosis
demonstrate that for some subgroups, primary prophylaxis with
pegfilgrastim will be the most cost-effective strategy at lower lev-
els of FN risk. Because the G-CSF market in the UK is driven by
competitive tenders, it is common for discounts to be provided on
list prices. Including the possible discounting of G-CSFs in the
modeling also greatly reduces the FN risk threshold at which pri-
mary prophylaxis with pegfilgrastim is cost-effective. The overall
decision as to whether to use G-CSFs will depend on the clinician’s
assessment of risk factors for a particular patient.
Currently there are two filgrastim biosimilars available in the
UK with list prices approximately 10% less than the originator
filgrastim (Neupogen) [43]. A sensitivity analysis of the cost of fil-
grastim was performed using a WTP threshold of £20,000. Regard-
less of the FN risk level, if the cost of filgrastim is reduced to 50% of
the list price, the most cost-effective strategies still do not involve
filgrastim.
Published cost-effectiveness analyses [44,45] for different
health-care systems have reached different conclusions regarding
the cost-effectiveness of G-CSF prophylaxis for FN and have more
closely supported international clinical guideline recommenda-
tions on the use of G-CSFs [7,12]. Differences in the conclusions of
these analyses are attributed to the use of different pegfilgrastim
t FN risk (no G-CSFs): 0.1 to 0.7
unt rate applied to drug prices: 0 to 0.6
t diagnosis : 40 to 65
d Ratio for survival if low RDI: 1 to 2.55
r stage at diagnosis: 1 to 4
tim compared to secondary prophylaxis withatien
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473V A L U E I N H E A L T H 1 4 ( 2 0 1 1 ) 4 6 5 – 4 7 4countries, and differences between the structures of the models
used.
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